title: Successful eradication of inhibitor in a patient with severe haemophilia B and anaphylaxis to factor IX concentrates: is there a role for Rituximab and desensitization therapy?
authors.affiliation: Department of Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL.
authors.forename: S
authors.initials: S
authors.lastname: Gamerman
authors.forename: A M
authors.initials: AM
authors.lastname: Singh
authors.forename: M
authors.initials: M
authors.lastname: Makhija
authors.forename: A
authors.initials: A
authors.lastname: Sharathkumar
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000378:metabolism* / Q000627:therapeutic use; D019774:Blood Coagulation Factor Inhibitors / Q000037:antagonists & inhibitors* / Q000097:blood; D001779:Blood Coagulation Factors / Q000627:therapeutic use*; D003029:Coagulants / Q000627:therapeutic use; D003888:Desensitization, Immunologic; D005164:Factor IX / Q000032:analysis; D015942:Factor VIIa / Q000627:therapeutic use; D006207:Half-Life; D002836:Hemophilia B / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007155:Immunologic Factors / Q000378:metabolism* / Q000627:therapeutic use; D007223:Infant; D020300:Intracranial Hemorrhages / Q000188:drug therapy / Q000209:etiology; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D019774:Blood Coagulation Factor Inhibitors; D001779:Blood Coagulation Factors; D003029:Coagulants; D007155:Immunologic Factors; D011994:Recombinant Proteins; C025667:prothrombin complex concentrates; D000069283:Rituximab; D005164:Factor IX; C103587:recombinant FVIIa; D015942:Factor VIIa